Awiqli weekly insulin extended to children aged 10 and older with type 2 diabetes

The once-weekly insulin that the Food and Drug Administration approved for adults in the spring can now be given to children. On 23 October 2026 the agency approved a supplement to the licence for Awiqli, Novo Nordisk's insulin icodec, that adds paediatric patients 10 years of age and older with type 2 diabetes to the drug's indication [s1]. The approval was recorded under biologics licence application 761326, supplement S-001, and the updated prescribing information carries a revision date of October 2026 [s1][s2].

Awiqli is a long-acting human insulin analogue designed to be injected once a week rather than once a day — a schedule that cuts a daily basal-insulin regimen from roughly 365 injections a year to about 52. The product is supplied in a U-700 FlexTouch prefilled pen that delivers doses in 10-unit increments, up to 700 units in a single injection [s2]. When the drug was first cleared for adults with type 2 diabetes in March 2026, the label noted that a paediatric programme was still outstanding. This supplement closes that gap.

What the label now says

The indication reads that Awiqli is "indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus" [s2]. The agency's own "recent major changes" notice dates the indications change to October 2026, confirming that the paediatric population is the new element rather than a restatement of the adult approval [s2].

Two boundaries are worth stating plainly. First, the lower age limit is firm: the label records that "the safety and effectiveness of Awiqli has not been established in pediatric patients with type 2 diabetes younger than 10 years of age" [s2]. Second, the indication is specific to type 2 diabetes. Awiqli is not approved for type 1 diabetes in any age group, and nothing in this supplement changes that.

How the FDA reached the decision

The paediatric clearance did not come from a large, dedicated efficacy trial in children. The label states that use of Awiqli in patients 10 and older "is supported by evidence from adequate and well-controlled studies in adults with type 2 diabetes mellitus and a pharmacokinetic study in pediatric patients 10 years of age and older with type 2 diabetes" [s2]. In other words, the regulator extrapolated efficacy from the adult trials and bridged the gap with a smaller study measuring how the drug behaves in children's bodies — a standard approach when a disease and a drug's mechanism are judged similar enough across ages.

That is a legitimate and common route, but it is a different evidentiary footing from a trial powered to show a glucose-lowering effect in children directly. Readers weighing the news should hold both facts together: the approval is real and FDA-sanctioned, and it rests on inference from adults plus paediatric pharmacokinetics rather than a children's outcome trial [s2].

Why a weekly insulin for teenagers matters

Adherence is one of the hardest problems in adolescent diabetes care. A once-weekly basal injection, if it controls glucose adequately, removes a large share of the daily burden that falls on young patients and their families. The trade-off is that a long-acting, slow-clearing insulin cannot be dialled back quickly, which is why the label's warnings about hypoglycaemia — including the instruction never to transfer Awiqli from its pen into a syringe, because an overdose and severe low blood sugar can follow — apply with particular force when a regimen is first being established [s2].

What to watch

The supplement approval letter instructs the company on the remaining post-marketing commitments that accompany a paediatric indication [s3]. Whether real-world use in this age group matches the glucose control seen in adults, and how hypoglycaemia rates track in younger patients, are the questions the label cannot yet answer and that surveillance will have to.

Red flags: a child or teenager on any insulin who becomes shaky, sweaty, confused, unusually drowsy or difficult to rouse may be having a dangerous low blood sugar and needs fast-acting sugar and urgent help. This article describes an FDA approval and is not medical advice. Decisions about starting, switching or dosing insulin for a young person belong with the treating diabetes team.